DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren D. Tesh, PharmD, BCPS
Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Susan Halabi, PhD
Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Philip C. Hoffman, MD
Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

Grzegorz S. Nowakowski, MD
Associate Professor of Medicine and Oncology
Mayo Clinic Rochester
Rochester, Minnesota

Vassiliki A. Papadimitrakopoulou, MD
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Department of Thoracic Head & Neck Medical Oncology
Division of Cancer Medicine
Houston, Texas

Courtney J. Preusse, MA
(Consumer Representative)
Senior Research Administrator and CLIA Operations Director
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Bruce J. Roth, MD
(Chairperson)
Professor of Medicine
Division of Oncology
Washington University School of Medicine
St. Louis, Missouri

ACTING INDUSTRY REPRESENTATIVE (Non-Voting)

Gary Gordon, MD, PhD
(Acting Industry Representative)
Vice President, Oncology Development
AbbVie, Inc.
North Chicago, Illinois
### TEMPORARY MEMBERS (Voting)

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Bollard, MD, FRACP, FRCPA</td>
<td>Bosworth Chair for Cancer Biology, Director, Center for Cancer and Immunology Research, Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine, Children’s National Health System, The George Washington University, School of Medicine and Health Sciences, Washington, District of Columbia</td>
</tr>
<tr>
<td>Andy Chen, MD PhD</td>
<td>Leader, Lymphoma Program, Knight Cancer Institute, Oregon Health &amp; Science University, Portland, Oregon</td>
</tr>
<tr>
<td>Arthur Flatau, PhD (Patient Representative)</td>
<td>Austin, Texas</td>
</tr>
<tr>
<td>Christopher S. Hourigan, DPhil, FACP</td>
<td>Chief, Myeloid Malignancies, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland</td>
</tr>
<tr>
<td>David Harrington, PhD, MA</td>
<td>Professor of Statistics and Biostatistics, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts</td>
</tr>
<tr>
<td>Anthony D. Sung, MD</td>
<td>Assistant Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina</td>
</tr>
</tbody>
</table>

### FDA PARTICIPANTS (Non-Voting)

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Pazdur, MD</td>
<td>Director, Oncology Center of Excellence, FDA, Acting Director, Office of Hematology &amp; Oncology Products (OHOP), Office of New Drugs (OND), CDER, FDA</td>
</tr>
<tr>
<td>Donna Przepiorka, MD PhD</td>
<td>Cross-Discipline Team Leader, DHP, OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Qing Xu, PhD</td>
<td>Statistical Reviewer, Division of Biometrics V, Office of Biostatistics, Office of Translational Sciences, CDER, FDA</td>
</tr>
<tr>
<td>Ann T. Farrell, MD</td>
<td>Director, Division of Hematology Products (DHP), OHOP, OND, CDER, FDA</td>
</tr>
<tr>
<td>Emily Jen, MD, PhD</td>
<td>Clinical Reviewer, DHP, OHOP, OND, CDER, FDA</td>
</tr>
</tbody>
</table>